SCHEMBL1532715

SCHEMBL1532715

O=C(O)c1cncc(OC(=O)N2CCC(Oc3ccc(OCc4cccc(F)c4)cc3)CC2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.62
NR4A2 P43354 2/20 0.52
ALKBH1 Q13686 1/20 0.45
MAOB P27338 6/20 0.44
MAOA P21397 3/20 0.44
MMP13 P45452 1/20 0.44
MMP14 P50281 1/20 0.44
PARP10 Q53GL7 1/20 0.44
PPARA Q07869 1/20 0.44
F10 P00742 1/20 0.44
GRIN2B Q13224 1/20 0.43
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
GFER P55789 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
MRGPRX4 Q96LA9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29976154 1.00 FAAH (0.62) FAAHNR4A2ALKBH1MAOBMAOA
SCHEMBL16333042 0.92 FAAH (0.61) FAAHMAOBMAOAMMP13MMP14
SCHEMBL1532829 0.91 FAAH (0.54) FAAHNR4A2MEN1HTTGFER
SCHEMBL1532838 0.90 FAAH (0.57) FAAHNR4A2MAOBMAOAMMP13
SCHEMBL1532790 0.87 FAAH (0.68) FAAHNR4A2MAOBMAOAMMP13
SCHEMBL1532894 0.86 FAAH (0.58) FAAHNR4A2MAOBMAOAMMP13
SCHEMBL1532895 0.86 FAAH (0.58) FAAHNR4A2MAOBMAOAMMP13
SCHEMBL12736284 0.86 FAAH (0.62) FAAHNR4A2ALKBH1MAOBMAOA
Oxalic Acid SCHEMBL1532922 0.85 FAAH (0.57) FAAHNR4A2MAOBMAOAMMP13
SCHEMBL2193693 0.85 FAAH (0.58) FAAHNR4A2ALKBH1MAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1849773-B1 Piperazine derivatives for the treatment of urinary incontinence and pain ASTELLAS PHARMA INC (JP) 2013-10-16 EP claimed
EP-2564849-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH PAINS IN URINARY ORGANS Astellas Pharma Inc. (JP) 2013-03-06 EP claimed
US-20130030006-A1 AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN ASTELLAS PHARMA INC. (JP) 2013-01-31 US claimed
US-7919495-B2 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound ASTELLAS PHARMA, INC. (JP) 2011-04-05 US claimed
US-20080306046-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative FMC CORPORATION (US) 2008-12-11 US claimed
EP-1849773-A1 PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE Astellas Pharma Inc. (JP) 2007-10-31 EP claimed
US-12637413-B2 Fatty acid amide hydrolase (FAAH) cleavable prodrugs of thyromimetics and combination with peripherally restricted FAAH inhibitors AUTOBAHN THERAPEUTICS, INC. (US) 2026-05-26 US disclosed
US-20250302775-A1 METHODS FOR THE TREATMENT OF DEPRESSION AUTOBAHN THERAPEUTICS, INC. 2025-10-02 US disclosed
US-20240261414-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS AUTOBAHN THERAPEUTICS INC (US) 2024-08-08 US disclosed
US-20240254075-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS AUTOBAHN THERAPEUTICS, INC. 2024-08-01 US disclosed
WO-2024054996-A1 METHODS FOR THE TREATMENT OF DEPRESSION AUTOBAHN THERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
EP-4334283-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS Autobahn Therapeutics, Inc. (US) 2024-03-13 EP disclosed
EP-2607362-B1 Piperidine and piperazine carboxylates as FAAH inhibitors ASTELLAS PHARMA INC (JP) 2014-12-31 EP disclosed
US-7919495-B2 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound ASTELLAS PHARMA, INC. (JP) 2011-04-05 US disclosed
US-7919494-B2 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound ASTELLAS PHARMA, INC. (JP) 2011-04-05 US disclosed
US-7915261-B2 Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound ASTELLAS PHARMA, INC. (JP) 2011-03-29 US disclosed
US-20100009972-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound ASTELLAS PHARMA INC. (JP) 2010-01-14 US disclosed
US-20100009971-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound ASTELLAS PHARMA INC. (JP) 2010-01-14 US disclosed
US-20080306046-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative FMC CORPORATION (US) 2008-12-11 US disclosed
EP-1849773-A1 PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE Astellas Pharma Inc. (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250302775-A1 METHODS FOR THE TREATMENT OF DEPRESSION TRHR, FAAH, TSHR FAAH 2/4885NR4A2 230/4885ALKBH1 1463/4885
US-12637413-B2 Fatty acid amide hydrolase (FAAH) cleavable prodrugs of thyromimetics and combination with peripherally restricted FAAH inhibitors FAAH, FAAH2, CNR2 FAAH 1/4885NR4A2 1285/4885ALKBH1 979/4885
US-20240254075-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF THYROMIMETICS AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS FAAH, FAAH2, FFAR1 FAAH 1/4885NR4A2 1360/4885ALKBH1 1126/4885
US-20240261414-A1 FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS FAAH, FAAH2, FFAR1 FAAH 1/4885NR4A2 1202/4885ALKBH1 2834/4885
US-20080306046-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative FAAH, FAAH2, APEH FAAH 1/4885NR4A2 2256/4885ALKBH1 139/4885
US-20100009972-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound FAAH, FAAH2, CNR2 FAAH 1/4885NR4A2 3109/4885ALKBH1 298/4885
US-20130030006-A1 AGENT FOR PREVENTING OR TREATING DISEASES ACCOMPANIED BY URINARY PAIN FAAH, FAAH2, PTGS1 FAAH 1/4885NR4A2 4271/4885ALKBH1 1152/4885
US-20100009971-A1 Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound FAAH, FAAH2, CNR1 FAAH 1/4885NR4A2 3138/4885ALKBH1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.